Home › Essential Thrombocythemia › Massachusetts › Boston
Essential Thrombocythemia clinical trials in Boston, MA
4 studies for Essential Thrombocythemia are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
RecruitingPhase 3
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center (Bidmc), Boston
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
RecruitingPhase 1
- Massachusetts General Hospital, Boston
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
RecruitingPhase 1
- Dana Farber Cancer Institute, Boston
Ruxolitinib in Thrombocythemia and Polycythemia Vera
RecruitingPhase 2
- Massachusetts General Hospital, Boston
- Beth-Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Essential Thrombocythemia trials in other cities
- New York City, NY7 studies
- Durham, NC6 studies
- Chicago, IL4 studies
- Salt Lake City, UT4 studies
- Baltimore, MD4 studies
- Miami, FL4 studies
- Nashville, TN4 studies
- Mountain View, CA4 studies
- Cleveland, OH3 studies
- Houston, TX3 studies
- St. Louis, MO3 studies
- Los Angeles, CA3 studies
Other studies in Boston
- Breast Cancer111 studies
- Non-Small Cell Lung Cancer90 studies
- Cancer (all types)86 studies
- Colorectal Cancer63 studies
- Metastatic Cancer63 studies
- Lung Cancer62 studies
- Ovarian Cancer61 studies
- Prostate Cancer59 studies
- Depression52 studies
- Endometrial Cancer50 studies
- Heart Failure44 studies
- Acute Myeloid Leukemia44 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.